Company Dossier - Biotech
Waltham, Massachusetts - Est. 2025
Fortitude Biomedicines
The antibody carries a poison in most drugs. Here it carries a shredder. That is the whole pitch - and it is worth understanding.
The antibody carries a poison in most drugs. Here it carries a shredder. That is the whole pitch - and it is worth understanding.
Here is a thing biotech press releases rarely say plainly: most antibody-drug conjugates work until the disease learns to route around them. Fortitude Biomedicines, which launched publicly in January 2026 from an office in Waltham, Massachusetts, thinks it has a way around that. The company is small - roughly twelve people - and its seed round, $13 million, is modest by the standards of a field where nine-figure launches are routine. What it is not modest about is the idea.
The idea is called GLUE-DAC, and the name does most of the explaining. An antibody-drug conjugate, or ADC, is a targeting missile: an antibody finds a specific cell, and a chemical payload tucked onto it does the damage. The trouble is that the classic payloads - cytotoxins - are blunt. Cells develop resistance. Dosing windows are narrow. You can only push so hard before you hurt the wrong tissue.
Fortitude's twist is to swap the payload. Instead of a poison, it attaches a molecular glue degrader - a small molecule that doesn't just block a target protein but recruits the cell's own disposal machinery to destroy it. And because degradation is catalytic, one glue molecule can take out many copies of a target before it's spent. In theory, that means more potency from less payload, a wider therapeutic window, and a route around the resistance that trips up conventional ADCs.
That is the theory, anyway. The useful thing about Fortitude's claim is that it is specific and testable. Catalytic degradation as an ADC payload either widens the therapeutic window in the clinic or it doesn't. This is not a company selling a vibe. It is a company making a falsifiable bet, which is exactly the kind worth watching.
The people making it have done this before. President and CEO Jesse Chen, Ph.D., is a repeat founder - previously involved with Triana Biomedicines and Avilar Therapeutics - and the scientific founder, Jin Wang, Ph.D., runs a pharmacology lab at Baylor College of Medicine where the degrader chemistry was born. Repeat founders are worth studying less for what they build than for what they decline to build. Fortitude has picked one hard problem and pointed most of its dozen people at it.
"GLUE-DAC is a powerful modality that aims to redefine precision medicines and bring new hope to patients."
The counterpoint comes from the science side. "Resistance is increasingly emerging as a challenge in the current ADC therapeutic landscape," says scientific founder Jin Wang. "The field urgently needs payloads with distinct mechanisms." Two founders, two vantage points, one thesis: the antibody was never the problem. The payload was.
A proprietary antibody-drug conjugate platform that uses molecular glue degraders as the therapeutic payload. By harnessing the catalytic nature of glues to degrade a target protein, it aims to expand the therapeutic window of ADCs, overcome resistance, and reach targets that conventional payloads can't touch.
A first-in-class T-cell targeting bispecific antibody aimed at disease-driven T-cell signaling for axial spondyloarthritis (AxSpA), a painful inflammatory spine disease. In IND-enabling studies, with a first-in-human clinic entry planned for the first half of 2027.
Notice the indication choice. Not the flashiest oncology headline, but axial spondyloarthritis - a real disease, real unmet need, and a place where precision immunology could hit disease-driving signaling without carpet-bombing the immune system. In biotech, indication selection is strategy. The molecule is only half the story.
$13 million is not a lot of money in biotech, and twelve people is not a big team. But early-stage science is less about headcount than about a single clear idea executed well. The seed round drew a cross-border syndicate - a quiet reminder that the best science increasingly ignores geography.
Co-led by K2 Bio Partners, SHAC and Elikon Venture - announced January 2026.
Serial biotech entrepreneur previously involved with Triana Biomedicines and Avilar Therapeutics. Now leading Fortitude's push to turn degrader chemistry into clinical drugs.
Michael E. DeBakey Endowed Professor in Pharmacology at Baylor College of Medicine, where the molecular glue and targeted protein degradation science underpinning GLUE-DAC originated.
Appointed in April 2026 to steer the clinical strategy as the lead program moves toward first-in-human studies.
President and CEO of Newleos Therapeutics, chairing the board of the young company.
Fortitude Biomedicines hasn't published its own interview or product-demo videos yet. In the meantime, these primers explain the science its whole thesis rests on - molecular glues and antibody-drug conjugates.
Note - Fortitude Biomedicines is a young, preclinical company; timelines (e.g. H1 2027 clinic entry) are stated targets, and some operational details are approximate. Figures reflect publicly reported information as of mid-2026.